Abstract Library

#4465 RET Lys666Asn has low MEN2-related tumours penetrance but may be associated with pheochromocytoma

Introduction: Multiple Endocrine Neoplasia type 2 (MEN2) is caused by germline pathogenic variants (PVs) in the RET proto-oncogene, leading to medullary thyroid carcinoma (MTC), pheochromocytoma, and primary hyperparathyroidism (PHPT). RET c.1998G>C, p.Lys666Asn is a rare PV, with 33 cases described thus far, and is associated with low penetrance of MEN2-related tumours, but its clinical significance remains incompletely understood.

Conference:

Presenting Author: Halperin R

Authors: Halperin R, Peshes-Yaloz N, Tirosh A, Twito O,

Keywords: MEN2, pheochromocytoma, hyperparathyroidism, medullary thyroid carcinoma,

#4323 The value of 68Ga-Exendin-4 PET/CT for benign and metastatic insulinoma

Introduction: Insulinoma is the most common functional pancreatic neuroendocrine tumour which is difficult to locate by conventional imaging. 68Ga-exendin-4 PET/CT is a promising technique for detecting benign insulinomas but is not definite for metastatic insulinomas.

Conference:

Presenting Author: Xu J

Authors: Xu J, Liang Y, Huang D, Chen J, Song S,

Keywords: insulinoma, 68Ga-exendin-4, PET/CT,

#4200 Risk of venous thromboembolism according to molecular profiling in patients with neuroendocrine carcinoma

Introduction: Venous thromboembolism (VTE) is a common complication in cancer patients, which negatively affects prognosis. Neuroendocrine carcinomas (NEC) are a rare and aggressive diseases, with low responses to treatment and poor prognosis. In this context, the use of molecular profiling is crucial for the identification of druggable alterations. However, data about VTE in NENs are scares, even though retrospective data describes rates in line with other high-risk malignancies.

Conference:

Presenting Author:

Authors: Gervaso L, Winchler C, Pisa E, Benini L, Cella C,

Keywords: VTE, NEC, molecular profiling, neuroendocrine carcinoma, venous thromboembolism,

#4090 Octreotide infusion pump in patients with functional neuroendocrine tumors and refractory hormonal syndromes

Introduction: In patients with metastatic functional neuroendocrine tumors (NETs), symptoms are, sometimes, not adequately controlled with long-acting somatostatin analogues (LASSAs), so patients need to use boost subcutaneous (sc) octreotide injections (inj) daily. However, this approach is not always effective and convenient for the patients.

Conference:

Presenting Author: Thuringer J

Authors: Thuringer J, Parker G, Sarma A, Hayes A, Mandair D,

Keywords: carcinoid syndrome, VIPoma, Octreotide, pump, refractory, subcutaneous,

#4056 High expression of ADAM15 in non-functional pancreatic neuroendocrine tumors is associated with high-density tumor-infiltrating neutrophils and predicts poor outcome

Introduction: Non-functional pancreatic neuroendocrine tumors (NF-PanNETs) displayed heterogeneous prognoses. Copy number variations (CNVs) of ADAM15 significantly increased in patients who underwent postoperative early recurrence. ADAM15 (a disintegrin and metalloproteinase 15) has been identified as a key molecule in progression and metastasis of many tumors, regulating immune infiltration. However, correlation between ADAM15 and NF-PanNETs remains unknown.

Conference:

Presenting Author:

Authors: Tang L, Ying Y, Peng M, Wang Y, Lou W,

Keywords: pancreatic neuroendocrine tumor, recurrence, metastasis, ADAM15, tumor-infiltrating neutrophils,